Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263795 | 0.77 | TGFBR1 (0.49) | MAPTKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL217044 | 0.75 | MAPT (1.00) | MAPTKDM4ELMNACYP3A4NR4A2 | |
| SCHEMBL18432090 | 0.73 | MAPT (0.58) | MAPTKDM4ELMNACYP3A4MAPK1 | |
| SCHEMBL11509799 | 0.73 | MAPT (0.58) | MAPTKDM4ELMNACYP3A4MEN1 | |
| SCHEMBL276214 | 0.73 | MAPT (0.58) | MAPTKDM4ELMNACYP3A4MAPK1 | |
| SCHEMBL13911028 | 0.73 | MAPT (0.58) | MAPTKDM4ELMNACYP3A4NR4A2 | |
| SCHEMBL14127360 | 0.73 | MAPT (0.58) | MAPTKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL19060870 | 0.73 | MAPT (0.58) | MAPTKDM4ELMNACYP3A4NR4A2 | |
| SCHEMBL196873 | 0.73 | MAPT (0.58) | MAPTKDM4EPDE4APDE4BPDE4C | |
| SCHEMBL523878 | 0.73 | MAPT (0.58) | MAPTKDM4ELMNACYP3A4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250154174-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-05-15 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4262975-B1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2025-03-05 | — | — | EP | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20070212570-A1 | Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency | CANON KABUSHIKI KAISHA (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070212570-A1 | Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency | CANON KABUSHIKI KAISHA (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070212570-A1 | Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency | CANON KABUSHIKI KAISHA (JP) | 2007-09-13 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7147935-B2 | Such as tetrakis(1-(5-heptyloxyphenyl)isoquinoline-C2,N) (pu-dichloro) iridium (III); for red luminescence; graphic arts | CANON KABUSHIKI KAISHA (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20060177694-A1 | Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency | CANON KABUSHIKI KAISHA (JP) | 2006-08-10 | — | — | US | disclosed |
| CN-1474826-A | Light emitting device and display | ������������ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| EP-1348711-A1 | LUMINESCENT ELEMENT AND DISPLAY | CANON KABUSHIKI KAISHA (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003057695-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030068526-A1 | Such as tetrakis(1-(5-heptyloxyphenyl)isoquinoline-C2,N) (pu-dichloro) iridium (III); for red luminescence; graphic arts | CANON KABUSHIKI KAISHA (JP) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154174-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | MAPT 4610/4885KDM4E 4193/4885PDE4A 960/4885 |
| US-20060177694-A1 | Comprises iridium complexes, coordination compounds; red phosphorescence; high efficiency | AP3M1, MLEC, MLX | MAPT 3497/4885KDM4E 3317/4885PDE4A 3881/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MAPT 735/4885KDM4E 1654/4885PDE4A 554/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | MAPT 2934/4885KDM4E 2151/4885PDE4A 4567/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | MAPT 735/4885KDM4E 1654/4885PDE4A 554/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | MAPT 682/4885KDM4E 1533/4885PDE4A 622/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | MAPT 4689/4885KDM4E 3820/4885PDE4A 1032/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | MAPT 3360/4885KDM4E 84/4885PDE4A 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.